{
  "company": "IQVIA Holdings",
  "ticker": "IQV",
  "period": {
    "from": "2026-03-26",
    "to": "2026-04-25",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 23,
    "negative": 8,
    "neutral": 33
  },
  "synthesis": {
    "executive_summary": "Sentiment analysis for IQVIA Holdings (IQV) from 2026-03-26 to 2026-04-25. Analyzed 64 items across FDA and news sources.",
    "key_findings": [],
    "overall_sentiment": "neutral"
  },
  "top_positive": [
    {
      "title": "AI-Powered Clinical Trial Site Feasibility Research Report 2026: $4.38 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
      "date": "2026-04-24",
      "source": "news",
      "score": 1.0
    },
    {
      "title": "$1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics",
      "date": "2026-04-09",
      "source": "news",
      "score": 0.943
    },
    {
      "title": "Drug Development Services Market Research Report 2026: $50+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
      "date": "2026-04-14",
      "source": "news",
      "score": 0.898
    },
    {
      "title": "AI-Based Clinical Trial Solution Providers Research Report 2026: $8.5+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
      "date": "2026-04-24",
      "source": "news",
      "score": 0.886
    },
    {
      "title": "Rare Disease Clinical Trials Research Report 2026: $21.34 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
      "date": "2026-04-24",
      "source": "news",
      "score": 0.878
    },
    {
      "title": "Early Phase Clinical Trial Outsourcing Research Report 2026: $14.8 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
      "date": "2026-04-24",
      "source": "news",
      "score": 0.875
    },
    {
      "title": "Decentralized Clinical Trials Research Report 2026: $19.55 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
      "date": "2026-04-24",
      "source": "news",
      "score": 0.863
    },
    {
      "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
      "date": "2026-04-17",
      "source": "alpha_vantage",
      "score": 0.711
    },
    {
      "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": 0.711
    },
    {
      "title": "Mental Health Clinical Trials Research Report 2026: $4.89 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
      "date": "2026-04-24",
      "source": "news",
      "score": 0.599
    }
  ],
  "top_negative": [
    {
      "title": "100,000 child genomes power rare disease and cancer research",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": -0.66
    },
    {
      "title": "IQVIA Holdings (IQV) Traded Lower Due to AI-Related Fears Despite Reporting In-Line Results",
      "date": "2026-04-15",
      "source": "news",
      "score": -0.612
    },
    {
      "title": "IQVIA Holdings (IQV) Traded Lower Due to AI-Related Fears Despite Reporting In-Line Results",
      "date": "2026-04-15",
      "source": "alpha_vantage",
      "score": -0.612
    },
    {
      "title": "Trending Industry Today: IQVIA Holdings Leads Losses In CRO Stocks",
      "date": "2026-04-23",
      "source": "alpha_vantage",
      "score": -0.602
    },
    {
      "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors",
      "date": "2026-04-24",
      "source": "alpha_vantage",
      "score": -0.2
    },
    {
      "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors",
      "date": "2026-04-23",
      "source": "alpha_vantage",
      "score": -0.2
    },
    {
      "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors",
      "date": "2026-04-16",
      "source": "alpha_vantage",
      "score": -0.2
    },
    {
      "title": "Board and pay up for vote as MFA Financial (NYSE: MFA) plans 2026 virtual meeting",
      "date": "2026-04-17",
      "source": "alpha_vantage",
      "score": -0.103
    }
  ],
  "raw_data": {
    "total_items": 64,
    "items": [
      {
        "source": "sec",
        "filing_type": "8-K",
        "title": "8-K  - Current report",
        "date": "2026-04-23",
        "url": "https://www.sec.gov/Archives/edgar/data/1478242/000119312526173771/0001193125-26-173771-index.htm",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Early Phase Clinical Trial Outsourcing Research Report 2026: $14.8 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
        "description": "The early phase clinical trial outsourcing market presents opportunities driven by rising personalized medicine focus, decentralized trials, and regulatory harmonization. Increasing biotech activity and AI-enabled analytics boost demand for specialized CROs. …",
        "url": "https://www.globenewswire.com/news-release/2026/04/24/3280610/28124/en/Early-Phase-Clinical-Trial-Outsourcing-Research-Report-2026-14-8-Bn-Market-Opportunities-Trends-Competitive-Landscape-Strategies-and-Forecasts-2020-2025-2025-2030F-2035F.html",
        "date": "2026-04-24",
        "published_at": "2026-04-24T09:07:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.875,
          "confidence": 0.88
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "AI-Powered Clinical Trial Site Feasibility Research Report 2026: $4.38 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
        "description": "The AI-powered clinical trial site feasibility market is poised for strong growth, fueled by rising complexity in trial designs, demand for data-driven planning, and expansion of global trials. Key opportunities include adopting AI-driven site selection model…",
        "url": "https://www.globenewswire.com/news-release/2026/04/24/3280609/28124/en/AI-Powered-Clinical-Trial-Site-Feasibility-Research-Report-2026-4-38-Bn-Market-Opportunities-Trends-Competitive-Landscape-Strategies-and-Forecasts-2020-2025-2025-2030F-2035F.html",
        "date": "2026-04-24",
        "published_at": "2026-04-24T09:05:00Z",
        "sentiment": {
          "label": "positive",
          "score": 1.0,
          "confidence": 1.0
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Decentralized Clinical Trials Research Report 2026: $19.55 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
        "description": "Key market opportunities in decentralized clinical trials include increased adoption of hybrid trial designs, AI-driven optimization, and virtual trial platforms driven by telemedicine and digital health expansions. This enhances patient recruitment efficienc…",
        "url": "https://www.globenewswire.com/news-release/2026/04/24/3280606/28124/en/Decentralized-Clinical-Trials-Research-Report-2026-19-55-Bn-Market-Opportunities-Trends-Competitive-Landscape-Strategies-and-Forecasts-2020-2025-2025-2030F-2035F.html",
        "date": "2026-04-24",
        "published_at": "2026-04-24T09:02:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.863,
          "confidence": 0.86
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Rare Disease Clinical Trials Research Report 2026: $21.34 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
        "description": "Key opportunities in the rare disease clinical trials market include expanding orphan drug programs, adopting virtual/hybrid trials, leveraging AI for optimization, decentralized trial models, and personalized medicine focus. Growth is driven by enhanced coll…",
        "url": "https://www.globenewswire.com/news-release/2026/04/24/3280605/28124/en/Rare-Disease-Clinical-Trials-Research-Report-2026-21-34-Bn-Market-Opportunities-Trends-Competitive-Landscape-Strategies-and-Forecasts-2020-2025-2025-2030F-2035F.html",
        "date": "2026-04-24",
        "published_at": "2026-04-24T09:01:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.878,
          "confidence": 0.88
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Mental Health Clinical Trials Research Report 2026: $4.89 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
        "description": "Key market opportunities in mental health clinical trials include the rise of digital interventions, personalized psychiatry research, decentralized trials, and AI-driven patient recruitment. This is fueled by growing mental health disorder prevalence and reg…",
        "url": "https://www.globenewswire.com/news-release/2026/04/24/3280602/28124/en/Mental-Health-Clinical-Trials-Research-Report-2026-4-89-Bn-Market-Opportunities-Trends-Competitive-Landscape-Strategies-and-Forecasts-2020-2025-2025-2030F-2035F.html",
        "date": "2026-04-24",
        "published_at": "2026-04-24T08:57:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.599,
          "confidence": 0.6
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "AI-Based Clinical Trial Solution Providers Research Report 2026: $8.5+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
        "description": "Key market opportunities include leveraging AI to optimize patient recruitment, enhance trial predictions, and streamline clinical operations. The rise of cloud-based and decentralized trial platforms, coupled with AI-driven data analytics and automation, dri…",
        "url": "https://www.globenewswire.com/news-release/2026/04/24/3280599/28124/en/AI-Based-Clinical-Trial-Solution-Providers-Research-Report-2026-8-5-Bn-Market-Opportunities-Trends-Competitive-Landscape-Strategies-and-Forecasts-2020-2025-2025-2030F-2035F.html",
        "date": "2026-04-24",
        "published_at": "2026-04-24T08:52:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.886,
          "confidence": 0.89
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "IQVIA Holdings (IQV) Traded Lower Due to AI-Related Fears Despite Reporting In-Line Results",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_c44e19f9-3cbc-418d-9410-73cda22da63e",
        "date": "2026-04-15",
        "published_at": "2026-04-15T13:47:59Z",
        "sentiment": {
          "label": "negative",
          "score": -0.612,
          "confidence": 0.61
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "IQVIA Holdings Earnings Preview: What to Expect",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_7a015b60-c723-4986-abbb-957eeac0b01e",
        "date": "2026-04-15",
        "published_at": "2026-04-15T10:49:35Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Drug Development Services Market Research Report 2026: $50+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F",
        "description": "The drug development services market presents significant opportunities due to the rise in R&D investments, AI adoption, personalized medicine, and emerging markets. Growth areas include preclinical research, regulatory optimization, and cloud-based data mana…",
        "url": "https://www.globenewswire.com/news-release/2026/04/14/3273662/28124/en/Drug-Development-Services-Market-Research-Report-2026-50-Bn-Opportunities-Trends-Competitive-Landscape-Strategies-and-Forecasts-2020-2025-2025-2030F-2035F.html",
        "date": "2026-04-14",
        "published_at": "2026-04-14T14:59:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.898,
          "confidence": 0.9
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "$1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics",
        "description": "The biopharmaceutical CXO market offers opportunities in strategic outsourcing, digital integration, resilient supply chains, and value-driven partnerships amidst evolving regulatory landscapes. The biopharmaceutical CXO market offers opportunities in strateg…",
        "url": "https://www.globenewswire.com/news-release/2026/04/09/3270735/28124/en/1-05-Bn-Biopharmaceutical-CXO-Markets-Global-Forecast-Report-2026-2032-How-Leading-Pharmas-Such-as-Pfizer-Roche-Novartis-Sanofi-and-AstraZeneca-Navigate-the-Evolving-Dynamics.html",
        "date": "2026-04-09",
        "published_at": "2026-04-09T10:05:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.943,
          "confidence": 0.94
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "IQVIA Holdings Inc. (IQV): Billionaire David Tepper Makes Minor Adjustment",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_aca927a4-f5a6-41e8-a121-330b5bf66fde",
        "date": "2026-04-07",
        "published_at": "2026-04-07T14:28:03Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Dermatomyositis Global Clinical Trials Market Review Report 2026: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status",
        "description": "The clinical trial report highlights opportunities in Dermatomyositis trials by revealing key trends in trial phases, sponsor types, and regions, particularly in G7 and E7 countries. It aids strategic decision-making by identifying prime trial locations and o…",
        "url": "https://www.globenewswire.com/news-release/2026/04/07/3269299/28124/en/Dermatomyositis-Global-Clinical-Trials-Market-Review-Report-2026-Region-Country-G7-E7-Trial-Status-Trial-Phase-Sponsor-Type-and-End-Point-Status.html",
        "date": "2026-04-07",
        "published_at": "2026-04-07T13:28:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_14b688ee-99d8-45eb-830b-c9df2dca0d5d",
        "date": "2026-04-05",
        "published_at": "2026-04-05T18:31:21Z",
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Calamos Wealth Management LLC Invests $11.93 Million in IQVIA Holdings Inc. $IQV",
        "url": "https://www.marketbeat.com/instant-alerts/filing-calamos-wealth-management-llc-invests-1193-million-in-iqvia-holdings-inc-iqv-2026-04-25/",
        "date": "2026-04-25",
        "summary": "Calamos Wealth Management LLC has acquired a new position in IQVIA Holdings Inc. (NYSE:IQV), purchasing 52,910 shares valued at approximately $11.93 million in the fourth quarter. Other institutional investors also adjusted their holdings in IQVIA, which currently has 89.62% of its stock owned by hedge funds and institutional investors. Analysts have a consensus \"Buy\" rating and a target price of $226.63 for IQVIA, with the company reporting strong quarterly earnings and providing positive FY 20",
        "sentiment_score": 0.490087,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Thermo Fisher Raises Outlook As Clario Deal Deepens AI Trial Capabilities",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-raises-outlook-as-clario-deal-deepens-ai-trial",
        "date": "2026-04-25",
        "summary": "Thermo Fisher Scientific has acquired clinical trial technology provider Clario, leading to a raised full-year revenue and EPS guidance. This acquisition integrates AI-driven clinical research capabilities, enhancing Thermo Fisher's offerings in trial efficiency and data quality. The company aims to leverage Clario's platform to strengthen its position in the competitive clinical research market, while analysts note potential risks related to debt and integration challenges.",
        "sentiment_score": 0.116415,
        "sentiment_label": "Neutral",
        "relevance_score": 0.619035,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors",
        "url": "https://www.msn.com/en-us/money/topstocks/iqvia-holdings-inc-stock-underperforms-thursday-when-compared-to-competitors/ar-AA21ACOr",
        "date": "2026-04-24",
        "summary": "IQVIA Holdings Inc. (IQV) stock fell on Thursday, underperforming its competitors. The stock closed down $2.77 to $257.26, while the S&P 500 also saw an increase.",
        "sentiment_score": -0.298683,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Iqvia stockholders approve new equity plan and reelect board members",
        "url": "https://m.investing.com/news/sec-filings/iqvia-stockholders-approve-new-equity-plan-and-reelect-board-members-93CH-4634384?ampMode=1",
        "date": "2026-04-23",
        "summary": "IQVIA Holdings Inc. stockholders approved a new 2026 Incentive and Stock Award Plan, replacing the 2017 plan, which allows for various equity-based awards tied to performance or continued employment. All nominated directors were reelected for one-year terms, and stockholders also approved the 2025 compensation for named executive officers and ratified PricewaterhouseCoopers LLP as the independent auditor. A proposal to separate the Chairman and CEO roles was not approved.",
        "sentiment_score": 0.24286,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Shareholders at IQVIA (NYSE: IQV) approve 2026 plan, keep chair-CEO",
        "url": "https://www.stocktitan.net/sec-filings/IQV/8-k-iqvia-holdings-inc-reports-material-event-6dfb97d5fe45.html",
        "date": "2026-04-23",
        "summary": "IQVIA Holdings Inc. stockholders approved the new 2026 Incentive and Stock Award Plan and re-elected all nominated directors at their Annual Meeting. They also ratified PricewaterhouseCoopers LLP as auditor and endorsed the 2025 executive compensation in an advisory vote. A shareholder proposal to separate the Chairman and CEO roles did not pass.",
        "sentiment_score": 0.143972,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Trending Industry Today: IQVIA Holdings Leads Losses In CRO Stocks",
        "url": "https://www.moomoo.com/news/post/68785677/trending-industry-today-iqvia-holdings-leads-losses-in-cro-stocks",
        "date": "2026-04-23",
        "summary": "IQVIA Holdings experienced significant losses, underperforming its CRO industry peers. This decline positions IQVIA as a key focus within the contract research organization sector due to its notable financial downturn.",
        "sentiment_score": -0.507265,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.602,
          "confidence": 0.6
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors",
        "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-thursday-when-compared-to-competitors-8ab5b227-79d8e24b8231",
        "date": "2026-04-23",
        "summary": "Shares of IQVIA Holdings Inc. (IQV) fell 8.29% on Thursday to $160.68, underperforming the broader market. This marks the stock's third consecutive day of losses, despite the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) also experiencing declines.",
        "sentiment_score": 0.014377,
        "sentiment_label": "Neutral",
        "relevance_score": 0.302304,
        "sentiment": {
          "label": "negative",
          "score": -0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Healthcare CRM Market Analysis By key Players Pegasystems Inc, SAP SE,etc",
        "url": "https://www.openpr.com/news/4483861/healthcare-crm-market-analysis-by-key-players-pegasystems-inc",
        "date": "2026-04-22",
        "summary": "The Healthcare CRM market is projected to grow significantly from US$ 5,750.95 million in 2022 to US$ 12,947.15 million by 2030, driven by the shift towards patient-centered models and integration with digital health technologies. The market is segmented by deployment, product type, application, and end-user, with North America leading and Asia-Pacific showing the fastest growth. Key players include Pegasystems Inc, SAP SE, and Oracle Corp, with continuous innovation focusing on AI enhancement a",
        "sentiment_score": 0.400245,
        "sentiment_label": "Bullish",
        "relevance_score": 0.825282,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. (NYSE:IQV) Receives Average Rating of \"Buy\" from Analysts",
        "url": "https://www.marketbeat.com/instant-alerts/iqvia-holdings-inc-nyseiqv-receives-average-rating-of-buy-from-analysts-2026-04-21/",
        "date": "2026-04-21",
        "summary": "IQVIA Holdings Inc. (NYSE:IQV) has received an average \"Buy\" rating from 17 research firms, with an average 12-month price target of $226.63. The company recently reported quarterly earnings that slightly beat estimates and issued strong FY2026 EPS guidance. Institutional investors hold a significant majority of the stock, reflecting considerable confidence in the company.",
        "sentiment_score": 0.648752,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc stock (US46266C1053): Why does its real-world data edge matter more for investors",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-inc-stock-us46266c1053-why-does-its-real-world-data-edge/69229993",
        "date": "2026-04-21",
        "summary": "IQVIA Holdings Inc. (US46266C1053) is a leader in healthcare intelligence, leveraging its real-world data and analytics to support drug development and commercialization. The company's integrated platform and focus on real-world evidence position it for growth, especially as regulators increasingly demand proof of drug effectiveness. Investors can benefit from IQVIA's data monetization strategy, resilience in the healthcare sector, and its critical role in digitizing life sciences, particularly ",
        "sentiment_score": 0.45832,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Royalty Pharma Approves Dividend and Expands J&J Research Funding",
        "url": "https://www.harianbasis.co/en/royalty-pharma-dividend-research-funding",
        "date": "2026-04-21",
        "summary": "Royalty Pharma (NASDAQ:RPRX) has declared a second-quarter dividend of $0.235 per share, payable on June 10, 2026. The company also announced a $500 million co-funding agreement with Johnson & Johnson for 2026 and 2027 to advance the development of JNJ-4804 for autoimmune diseases. Morgan Stanley recently increased its price target for RPRX from $61 to $63, maintaining an Overweight rating.",
        "sentiment_score": 0.111314,
        "sentiment_label": "Neutral",
        "relevance_score": 0.606388,
        "sentiment": {
          "label": "positive",
          "score": 0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "alpha_vantage",
        "title": "BMO Capital Initiates Coverage of IQVIA Holdings (IQV) with Outperform Recommendation",
        "url": "https://www.msn.com/en-us/money/savingandinvesting/bmo-capital-initiates-coverage-of-iqvia-holdings-iqv-with-outperform-recommendation/ar-AA1Qo3Rd?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-04-20",
        "summary": "BMO Capital has initiated coverage on IQVIA Holdings (IQV) with an Outperform rating. This new coverage suggests a positive outlook from the financial institution regarding IQVIA's stock performance and business prospects.",
        "sentiment_score": 0.430983,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc stock (US46266C1053): Why Google Discover changes matter more now",
        "url": "https://www.ad-hoc-news.de/news/ueberblick/iqvia-holdings-inc-stock-us46266c1053-why-google-discover-changes/69211233",
        "date": "2026-04-20",
        "summary": "Google's 2026 Discover Core Update is revolutionizing how investors access news on IQVIA Holdings Inc (IQV) by prioritizing personalized, mobile-first feeds that deliver real-time insights on healthcare analytics, clinical research, and pharma services. This shift means tailored financial stories on IQVIA's key segments, growth drivers, and market positioning will proactively appear in users' Google app feeds, enabling faster opportunity spotting and more informed investment decisions. The updat",
        "sentiment_score": 0.510339,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc stock (US46266C1053): Why Google Discover changes matter more now",
        "url": "https://www.ad-hoc-news.de/news/ueberblick/iqvia-holdings-inc-stock-us46266c1053-why-google-discover-changes/69207990",
        "date": "2026-04-19",
        "summary": "Google's 2026 Discover Core Update is significantly changing how investors access news about IQVIA Holdings Inc (US46266C1053) stock, delivering personalized healthcare analytics and clinical research insights directly to mobile feeds. This mobile-first evolution prioritizes visual, high-density financial content, leveraging user activity to provide real-time information on revenue growth, R&D trends, and market positioning without the need for traditional searches. The update aims to provide in",
        "sentiment_score": 0.486241,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc stock (US46266C1053): Why Google Discover changes matter more now",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/iqvia-holdings-inc-stock-us46266c1053-why-google-discover-changes/69207990",
        "date": "2026-04-19",
        "summary": "Google's 2026 Discover Core Update is significantly changing how investors access news for IQVIA Holdings Inc (US46266C1053) on mobile devices. The update prioritizes personalized, mobile-first financial content, leveraging user activity to deliver relevant insights on healthcare analytics, clinical research, and financial metrics directly to their feeds. This shift provides investors with quicker access to high-quality, E-E-A-T-compliant information, enhancing decision-making in the dynamic hea",
        "sentiment_score": 0.425004,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc stock (US46266C1053): Why Google Discover changes matter more now",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-inc-stock-us46266c1053-why-google-discover-changes/69207990",
        "date": "2026-04-19",
        "summary": "Google's 2026 Discover Core Update is significantly changing how investors access news for stocks like IQVIA Holdings Inc (US46266C1053), prioritizing mobile-first and personalized delivery of healthcare analytics and clinical research insights directly to user feeds. This update leverages past interests to provide proactive information on revenue growth, R&D trends, and market positioning, enhancing timing and efficiency for investors. By favoring high-density, credible content with strong E-E-",
        "sentiment_score": 0.52694,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc stock (US46266C1053): Why Google Discover changes matter more now",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/iqvia-holdings-inc-stock-us46266c1053-why-google-discover-changes/69195633",
        "date": "2026-04-18",
        "summary": "Google's 2026 Discover Core Update is significantly changing how content about IQVIA Holdings Inc stock is delivered to mobile users, prioritizing personalized, visual feeds over traditional search rankings. This shift and its emphasis on frequent, timely, and visual content amplification can accelerate investor awareness and influence sentiment for IQVIA, a leader in clinical data and trials. The article explains how this update provides retail investors with an informational edge by quickly di",
        "sentiment_score": 0.418095,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc stock (US46266C1053): Why Google Discover changes matter more now",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-inc-stock-us46266c1053-why-google-discover-changes/69195633",
        "date": "2026-04-18",
        "summary": "The article discusses how Google's 2026 Discover Core Update significantly changes how information about IQVIA Holdings Inc. (IQV) stock is consumed. It emphasizes that Discover's personalized, visual feeds will increase investor awareness by proactively delivering tailored content on healthcare analytics and clinical trials to mobile users. This shift is highlighted as crucial for IQVIA's visibility, disseminating information faster, and influencing investor sentiment, particularly for retail i",
        "sentiment_score": 0.470061,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Whittier Trust Co. Has $4.04 Million Stake in IQVIA Holdings Inc. $IQV",
        "url": "https://www.marketbeat.com/instant-alerts/filing-whittier-trust-co-has-404-million-stake-in-iqvia-holdings-inc-iqv-2026-04-18/",
        "date": "2026-04-18",
        "summary": "Whittier Trust Co. significantly reduced its stake in IQVIA Holdings Inc. by 54.6%, leaving them with 16,783 shares valued at approximately $4.04 million. Despite this, IQVIA reported strong Q4 results, exceeding revenue and EPS estimates, and issued positive guidance for FY2026. The company maintains a consensus \"Buy\" rating from analysts, with an average price target of $226.63.",
        "sentiment_score": 0.233722,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc stock (US46266C1053): Is real-world evidence now the real growth driver?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-inc-stock-us46266c1053-is-real-world-evidence-now-the/69189609",
        "date": "2026-04-18",
        "summary": "IQVIA Holdings Inc. (US46266C1053) is positioned as a key player in the life sciences industry, leveraging real-world evidence and data analytics to accelerate drug development and commercialization. The company's integrated model, combining R&D solutions, real-world solutions, and technology, provides essential services to pharma giants and offers investors exposure to a resilient business model less dependent on individual drug pipelines. With strong analyst sentiment and a focus on AI integra",
        "sentiment_score": 0.476987,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Morgan Stanley Lifts Vertex Pharmaceuticals (VRTX) PT on Updated Biopharma Models",
        "url": "https://www.insidermonkey.com/blog/morgan-stanley-lifts-vertex-pharmaceuticals-vrtx-pt-on-updated-biopharma-models-1740603/",
        "date": "2026-04-18",
        "summary": "Morgan Stanley has raised its price target for Vertex Pharmaceuticals (VRTX) to $612 from $596, maintaining an Overweight rating. This decision follows updated biopharma models reflecting IQVIA trends and intra-quarter developments ahead of Q1 earnings. RBC Capital Markets also recently increased its price target for VRTX, citing a preview of Q1 biotech results and potential M&A activity balancing seasonal pressures.",
        "sentiment_score": 0.106525,
        "sentiment_label": "Neutral",
        "relevance_score": 0.631443,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA to Announce First-Quarter 2026 Results on May 5, 2026",
        "url": "https://www.businesswire.com/news/home/20260415237583/en/IQVIA-to-Announce-First-Quarter-2026-Results-on-May-5-2026",
        "date": "2026-04-17",
        "summary": "IQVIA Holdings Inc. (NYSE: IQV) will announce its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The company's management will also host a conference call and webcast at 9:00 a.m. Eastern Time on the same day. Interested parties can find the earnings release, financial information, and registration details on the IQVIA Investor Relations website.",
        "sentiment_score": 0.005657,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "How New Real-World INGREZZA Data Versus AUSTEDO XR Will Impact Neurocrine Biosciences (NBIX) Investors",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/how-new-real-world-ingrezza-data-versus-austedo-xr-will-impa/amp",
        "date": "2026-04-17",
        "summary": "Neurocrine Biosciences reported new real-world data indicating that patients with tardive dyskinesia treated with INGREZZA demonstrated greater treatment persistence and fewer medication switches compared to those on AUSTEDO XR over six months. This analysis, using data from nearly 3,000 patients, could influence how healthcare providers and payers perceive INGREZZA as a first-line treatment. The article discusses how this data supports INGREZZA's market position, alongside the company's efforts",
        "sentiment_score": 0.146425,
        "sentiment_label": "Neutral",
        "relevance_score": 0.631364,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Board and pay up for vote as MFA Financial (NYSE: MFA) plans 2026 virtual meeting",
        "url": "https://www.stocktitan.net/sec-filings/MFA/def-14a-mfa-financial-inc-definitive-proxy-statement-b258983e5964.html",
        "date": "2026-04-17",
        "summary": "MFA Financial (NYSE: MFA) has announced its 2026 virtual annual meeting for June 3, 2026, where shareholders will vote on the election of two Class I directors, the ratification of KPMG LLP as the independent auditor, and an advisory Say-on-Pay resolution for executive compensation. The proxy statement details executive compensation for 2025, showing CEO Craig L. Knutson and President/CIO Bryan Wulfsohn received substantial salaries and incentive pay, with a significant portion of their compensa",
        "sentiment_score": 0.137623,
        "sentiment_label": "Neutral",
        "relevance_score": 0.618108,
        "sentiment": {
          "label": "negative",
          "score": -0.103,
          "confidence": 0.1
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Banco Bilbao Vizcaya Argentaria SA Stock (BBVA) Moved Up by 3.77% on Apr 17: Facts Behind the Movement",
        "url": "https://www.tradingkey.com/news/market-movers/261796254-market-movers-bbva-20260417",
        "date": "2026-04-17",
        "summary": "Banco Bilbao Vizcaya Argentaria SA (BBVA) saw its stock price increase by 3.77% on April 17, despite initial selling pressure from analyst downgrades. The stock's rebound was driven by strong 2025 financial results, including record net profit and robust shareholder returns, alongside a supportive Spanish economic outlook and efforts by the European Central Bank. Technical indicators showed mixed signals, with a buy signal from MACD but neutral RSI and oversold Williams %R.",
        "sentiment_score": -0.326201,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 0.564756,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Parker-Hannifin Corp Stock (PH) Moved Up by 3.63% on Apr 17: Key Drivers Unveiled",
        "url": "https://www.tradingkey.com/news/market-movers/261796252-market-movers-ph-20260417",
        "date": "2026-04-17",
        "summary": "Parker-Hannifin Corp (PH) stock rose by 3.63% on April 17, driven by strong Q2 fiscal year 2026 earnings, increased full-year guidance, and positive analyst \"Moderate Buy\" ratings with upward price targets. The company is benefiting from broader industrial sector strength, including trends like onshoring and infrastructure investments, and anticipation of its upcoming Q3 earnings report on April 30, 2026. Despite positive momentum, risks include institutional selling, executive share sales, prem",
        "sentiment_score": -0.321537,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 0.693645,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
        "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-a0cf5a7a-3d9eaf639b86",
        "date": "2026-04-17",
        "summary": "IQVIA Holdings Inc. (IQV) saw its stock rise by 2.62% to $176.46 on Friday, outperforming the broader market during a positive trading session where the S&P 500 Index and Dow Jones Industrial Average also increased. Despite this gain, the company's stock closed 28.57% below its 52-week high of $247.05, achieved on January 9th.",
        "sentiment_score": 0.265014,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.711,
          "confidence": 0.71
        }
      },
      {
        "source": "alpha_vantage",
        "title": "US prescriptions for Lilly's Foundayo were 1,390 for week ended April 10 - IQVIA data shared by analyst shows",
        "url": "https://www.marketscreener.com/news/us-prescriptions-for-lilly-s-foundayo-were-1-390-for-week-ended-april-10-iqvia-data-shared-by-anal-ce7e50d2df8ff527",
        "date": "2026-04-17",
        "summary": "IQVIA data, as shared by an analyst, indicates that US prescriptions for Lilly's new drug Foundayo totaled 1,390 for the week ending April 10. This news follows earlier reports about Lilly's obesity pill also drawing 1,390 US prescriptions in its launch week, suggesting a strong initial uptake for the pharmaceutical company's new offerings.",
        "sentiment_score": 0.149958,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.34,
          "confidence": 0.34
        }
      },
      {
        "source": "alpha_vantage",
        "title": "GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?",
        "url": "https://www.tradingkey.com/analysis/stocks/us-stocks/261793997-openai-gpt-rosalind-cro-tradingkey",
        "date": "2026-04-17",
        "summary": "OpenAI's new life sciences LLM, GPT-Rosalind, has caused a slump in the Contract Research Organization (CRO) sector due to its potential to increase R&D efficiency, particularly impacting pre-clinical CROs. While clinical CROs like IQVIA are less vulnerable due to their high-touch services and data assets, investors are advised to differentiate between sub-sectors. The article also highlights the competitive landscape between OpenAI and Google in life sciences AI and suggests opportunities for C",
        "sentiment_score": -0.102386,
        "sentiment_label": "Neutral",
        "relevance_score": 0.923184,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings (IQV) Gets a Buy from RBC Capital",
        "url": "https://www.theglobeandmail.com/investing/markets/stocks/IQV-N/pressreleases/1358432/iqvia-holdings-iqv-gets-a-buy-from-rbc-capital/",
        "date": "2026-04-17",
        "summary": "RBC Capital maintained a Buy rating on IQVIA Holdings (IQV) with a price target of $221.00, following a report from analyst Ryan Halsted. The company reported strong quarterly revenues of $4.36 billion and a net profit of $514 million for the quarter ending December 31. While Evercore ISI also issued a Buy rating, Citi assigned a Hold rating to IQVIA Holdings.",
        "sentiment_score": 0.027002,
        "sentiment_label": "Neutral",
        "relevance_score": 0.319041,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA stock falls as OpenAI unveils AI drug discovery model",
        "url": "https://m.investing.com/news/stock-market-news/iqvia-stock-falls-as-openai-unveils-ai-drug-discovery-model-93CH-4618987?ampMode=1",
        "date": "2026-04-16",
        "summary": "IQVIA Holdings shares dropped 2% after OpenAI announced GPT-Rosalind, a new AI model for accelerating drug discovery. This model aims to help researchers analyze large data volumes and convert scientific studies into healthcare applications, marking OpenAI's entry into the AI-driven scientific research field. Initial users include Amgen Inc., Moderna Inc., and the Allen Institute.",
        "sentiment_score": -0.404243,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA stock falls as OpenAI unveils AI drug discovery model",
        "url": "https://www.investing.com/news/stock-market-news/iqvia-stock-falls-as-openai-unveils-ai-drug-discovery-model-93CH-4618987",
        "date": "2026-04-16",
        "summary": "IQVIA Holdings (NYSE: IQV) shares fell 2% after OpenAI announced its entry into AI-driven drug discovery with GPT-Rosalind, a new model for life sciences research. The model aims to help researchers extract insights from data and convert scientific studies into healthcare applications. Initial users include Amgen, Moderna, and the Allen Institute, signaling OpenAI's push into applied AI for scientific breakthroughs.",
        "sentiment_score": -0.419134,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors",
        "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-thursday-when-compared-to-competitors-d7c86aec-3d54667572bf",
        "date": "2026-04-16",
        "summary": "IQVIA Holdings Inc. (IQV) stock fell by 3.45% on Thursday, closing at $171.95, despite an overall positive trading day for the broader market. This decline broke a three-day winning streak for the company's shares. The S&P 500 Index and the Dow Jones Industrial Average both saw gains on the same day.",
        "sentiment_score": -0.404835,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "KBC Group NV Boosts Stock Holdings in IQVIA Holdings Inc. $IQV",
        "url": "https://www.marketbeat.com/instant-alerts/filing-kbc-group-nv-boosts-stock-holdings-in-iqvia-holdings-inc-iqv-2026-04-16/",
        "date": "2026-04-16",
        "summary": "KBC Group NV increased its stake in IQVIA Holdings Inc. by 68.2% in Q4, adding 315,883 shares to own a total of 779,128 shares valued at $175.62 million. Other institutional investors also showed significant interest in IQVIA, with Brighton Jones LLC boosting its position by 244.4% and Empowered Funds LLC by 102.1%. Analysts maintain a consensus \"Buy\" rating for IQVIA with an average target price of $226.63, following the company's Q4 earnings beat and strong revenue growth.",
        "sentiment_score": 0.385479,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.318,
          "confidence": 0.32
        }
      },
      {
        "source": "alpha_vantage",
        "title": "RBC Capital Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $221",
        "url": "https://www.moomoo.com/news/post/68381059/rbc-capital-maintains-iqvia-holdings-iqvus-with-buy-rating-maintains",
        "date": "2026-04-16",
        "summary": "RBC Capital has reaffirmed its Buy rating on IQVIA Holdings (IQV.US) and maintained its price target at $221. This indicates continued confidence in the company's performance and future outlook from the analyst firm.",
        "sentiment_score": 0.4241,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA to Announce First-Quarter 2026 Results on May 5, 2026",
        "url": "https://www.biospace.com/press-releases/iqvia-to-announce-first-quarter-2026-results-on-may-5-2026",
        "date": "2026-04-16",
        "summary": "IQVIA Holdings Inc. (NYSE: IQV) will announce its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The company will also host a conference call and webcast at 9:00 a.m. Eastern Time on the same day for management to discuss the results. Interested parties can access the earnings release, financial information, and webcast details on the IQVIA Investor Relations website.",
        "sentiment_score": 0.108641,
        "sentiment_label": "Neutral",
        "relevance_score": 0.93901,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA to Announce First-Quarter 2026 Results on May 5, 2026",
        "url": "https://www.pharmiweb.com/press-release/2026-04-15/iqvia-to-announce-first-quarter-2026-results-on-may-5-2026",
        "date": "2026-04-15",
        "summary": "IQVIA Holdings Inc. will announce its first-quarter 2026 financial results before market open on Tuesday, May 5, 2026. The management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on the same day. Details for accessing the earnings release, webcast, and conference call registration are available on the IQVIA Investor Relations website.",
        "sentiment_score": 0.041488,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA will post quarterly results before the bell on May 5",
        "url": "https://www.stocktitan.net/news/IQV/iqvia-to-announce-first-quarter-2026-results-on-may-5-wqbw8qctvouz.html",
        "date": "2026-04-15",
        "summary": "IQVIA Holdings Inc. (NYSE: IQV) is scheduled to announce its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The company will also host a conference call and webcast at 9:00 a.m. Eastern Time on the same day to discuss the results. Interested parties can find the earnings release and webcast details on IQVIA's Investor Relations website.",
        "sentiment_score": 0.429752,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Massachusetts Financial Services Co. MA Buys 27,510 Shares of IQVIA Holdings Inc. $IQV",
        "url": "https://www.marketbeat.com/instant-alerts/filing-massachusetts-financial-services-co-ma-buys-27510-shares-of-iqvia-holdings-inc-iqv-2026-04-15/",
        "date": "2026-04-15",
        "summary": "Massachusetts Financial Services Co. increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 13.8%, purchasing an additional 27,510 shares to reach a total of 226,646 shares valued at $51.09 million. This move comes as IQVIA recently surpassed quarterly earnings and revenue estimates, reporting 10.3% year-over-year revenue growth. The company maintains an average \"Buy\" rating from Wall Street analysts with a target price of $226.63, and set its FY2026 EPS guidance between $12.55 and $12.85.",
        "sentiment_score": 0.391509,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Earnings Preview: What to Expect",
        "url": "https://www.inkl.com/news/iqvia-holdings-earnings-preview-what-to-expect",
        "date": "2026-04-15",
        "summary": "IQVIA Holdings (IQV) is expected to announce its FY2026 Q1 earnings soon, with analysts projecting a diluted profit of $2.51 per share, a 5.9% increase year-over-year. The company has a strong track record of exceeding consensus estimates and recently launched IQVIA.ai, an AI platform developed with NVIDIA, which has boosted investor confidence. Wall Street analysts maintain a \"Strong Buy\" rating for IQVIA, forecasting significant EPS growth and a substantial upside from current price levels.",
        "sentiment_score": 0.513235,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Assetmark Inc. Purchases 43,436 Shares of IQVIA Holdings Inc. $IQV",
        "url": "https://www.marketbeat.com/instant-alerts/filing-assetmark-inc-purchases-43436-shares-of-iqvia-holdings-inc-iqv-2026-04-15/",
        "date": "2026-04-15",
        "summary": "Assetmark Inc. significantly increased its stake in IQVIA Holdings Inc. by 33.6% in the fourth quarter, purchasing an additional 43,436 shares, bringing its total to 172,625 shares valued at $38.91 million. This increase makes Assetmark Inc. a 0.10% owner of IQVIA. Other institutional investors have also adjusted their holdings in IQVIA, which recently beat quarterly earnings expectations and received an average \"Buy\" rating from analysts with a target price of $226.63.",
        "sentiment_score": 0.340476,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings (IQV) Traded Lower Due to AI-Related Fears Despite Reporting In-Line Results",
        "url": "https://www.insidermonkey.com/blog/iqvia-holdings-iqv-traded-lower-due-to-ai-related-fears-despite-reporting-in-line-results-1738538/",
        "date": "2026-04-15",
        "summary": "IQVIA Holdings (IQV) shares traded lower despite reporting in-line results, attributed to AI-related fears, as noted by Oakmark Global Select Fund. Management believes the demand environment has stabilized and sees IQVIA as a net beneficiary of AI due to its proprietary data and expertise. The company was the top detractor for the Oakmark fund in Q1 2026, though the fund maintains a long-term positive outlook, expecting a recovery in client spending.",
        "sentiment_score": 0.035407,
        "sentiment_label": "Neutral",
        "relevance_score": 0.331761,
        "sentiment": {
          "label": "negative",
          "score": -0.612,
          "confidence": 0.61
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Medpace Holdings Inc stock (US5840631062): Is its CRO execution strong enough to unlock new upside?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/medpace-holdings-inc-stock-us5840631062-is-its-cro-execution-strong/69158542",
        "date": "2026-04-15",
        "summary": "Medpace Holdings Inc operates as a full-service Clinical Research Organization (CRO), providing comprehensive services for clinical trials with a focus on complex areas like oncology and rare diseases. The company's business model emphasizes recurring revenue from long-duration studies, proprietary technology, and a lean structure, positioning it as a key partner for biotech and pharmaceutical companies seeking efficient drug development. For investors, Medpace offers exposure to the stable heal",
        "sentiment_score": 0.201838,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.607725,
        "sentiment": {
          "label": "positive",
          "score": 0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Earnings Preview: What to Expect",
        "url": "https://markets.chroniclejournal.com/chroniclejournal/article/barchart-2026-4-15-iqvia-holdings-earnings-preview-what-to-expect",
        "date": "2026-04-15",
        "summary": "IQVIA Holdings (IQV) is expected to announce its FY2026 Q1 earnings soon. Analysts anticipate a diluted EPS of $2.51, a 5.9% increase year over year, with the company historically exceeding consensus estimates in three out of the last four quarters. The company recently launched IQVIA.ai, an AI platform developed in collaboration with NVIDIA, which has been met with a positive investor response and a \"Strong Buy\" consensus rating from Wall Street analysts.",
        "sentiment_score": 0.025757,
        "sentiment_label": "Neutral",
        "relevance_score": 0.319149,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
        "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-39c60bc0-708c2bdc08e9",
        "date": "2026-04-14",
        "summary": "IQVIA Holdings Inc. (IQV) stock increased by 1.91% to $175.28 on Tuesday, outpacing the broader market which also saw gains with the S&P 500 Index rising 1.18% and the Dow Jones Industrial Average up 0.66%. This performance marked the second consecutive day of gains for IQVIA Holdings Inc.",
        "sentiment_score": 0.486343,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.711,
          "confidence": 0.71
        }
      },
      {
        "source": "alpha_vantage",
        "title": "100,000 child genomes power rare disease and cancer research",
        "url": "https://www.stocktitan.net/news/ILMN/illumina-and-the-center-for-data-driven-discovery-in-biomedicine-q0dgshhktb0n.html",
        "date": "2026-04-14",
        "summary": "Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) announced a partnership to analyze 100,000 whole genomes from pediatric patients for rare disease and cancer research. This cloud-based platform uses advanced software to enable real-time genomic discovery and will be accessible via the Kids First Data Resource Center, supporting ARPA-H's Pediatric Care eXpansion to link data across over 200 pediatric institutions. The initiative aims to accelerate research tra",
        "sentiment_score": -0.232956,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 0.613604,
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Assessing IQVIA Holdings (IQV) Valuation After New AI Collaboration And Life Sciences Partnerships",
        "url": "https://www.sahmcapital.com/news/content/assessing-iqvia-holdings-iqv-valuation-after-new-ai-collaboration-and-life-sciences-partnerships-2026-04-13",
        "date": "2026-04-14",
        "summary": "IQVIA Holdings (IQV) is gaining attention due to new AI collaborations with NVIDIA and strategic life sciences partnerships, despite recent share price declines. The company's stock is currently assessed as undervalued by some metrics, with an estimated intrinsic discount, suggesting potential upside if future growth expectations are met. Investors are encouraged to review the company's financial data and risks, including potential pricing pressure and regulatory uncertainty.",
        "sentiment_score": 0.40893,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research",
        "url": "https://sg.finance.yahoo.com/news/labcorp-introduces-ai-powered-real-110000593.html",
        "date": "2026-04-14",
        "summary": "Labcorp has launched a new AI-powered real-world data platform, developed with Amazon Web Services (AWS) and Datavant, to accelerate Alzheimer's research and drug development. The platform utilizes de-identified healthcare data, including Labcorp's diagnostic and genomic datasets, combined with AI analytics to streamline data analysis, identify patient cohorts, and measure treatment effectiveness, ultimately aiming to shorten drug development timelines and improve patient outcomes. This innovati",
        "sentiment_score": 0.214702,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.641035,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. $IQV Stock Holdings Lessened by Running Oak Capital LLC",
        "url": "https://www.marketbeat.com/instant-alerts/filing-iqvia-holdings-inc-iqv-stock-holdings-lessened-by-running-oak-capital-llc-2026-04-13/",
        "date": "2026-04-14",
        "summary": "Running Oak Capital LLC reduced its stake in IQVIA Holdings Inc. by 16.0% in Q4, selling 14,527 shares and now holding 76,219 shares valued at $17.18 million. Despite this, IQVIA remains 2.2% of Running Oak Capital's portfolio and its sixth-largest holding. Institutional investors collectively own 89.62% of IQVIA, with several major firms increasing or initiating positions. Analysts maintain a \"Buy\" rating for IQVIA with a consensus price target of $226.63, significantly higher than its current ",
        "sentiment_score": 0.272302,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Hardman Johnston Global Advisors LLC Has $24.77 Million Holdings in IQVIA Holdings Inc. $IQV",
        "url": "https://www.marketbeat.com/instant-alerts/filing-hardman-johnston-global-advisors-llc-has-2477-million-holdings-in-iqvia-holdings-inc-iqv-2026-04-13/",
        "date": "2026-04-14",
        "summary": "Hardman Johnston Global Advisors LLC decreased its stake in IQVIA Holdings Inc. by 8.2% in the fourth quarter, now holding 109,907 shares valued at $24.77 million. Despite this reduction, IQVIA reported strong Q4 earnings, beating analyst estimates with $3.42 EPS and $4.36 billion in revenue, and provided optimistic FY2026 guidance. Analysts currently have a consensus \"Buy\" rating for IQV with an average target price significantly above its current trading price.",
        "sentiment_score": 0.480688,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      }
    ]
  }
}